

## **ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023**

Conference Call Scheduled for Friday, May 12, 2023 at 9:00 AM ET

PORTLAND, Maine, May 04, 2023 — **ImmuCell Corporation (Nasdaq: ICCC)** (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023.

The Company has scheduled a conference call the next morning, Friday, May 12, 2023, at 9:00 AM ET to review its first quarter financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until May 19, 2023 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #3163870.

The Company expects to file its Quarterly Report on Form 10-Q after the market closes on Thursday, May 11, 2023. The Company anticipates no change to the preliminary sales results for the first quarter of 2023 that were disclosed on April 5, 2023.

Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at [www.immuCell.com](http://www.immuCell.com), or by request to the Company, after the market closes on Thursday, May 11, 2023.

### **About ImmuCell:**

ImmuCell Corporation’s (**Nasdaq: ICCC**) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves.

ImmuCell manufactures and markets **First Defense**<sup>®</sup>, providing **Immediate Immunity**<sup>™</sup> to newborn dairy and beef calves, and is in the late stages of developing **Re-Tain**<sup>®</sup>, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: <http://www.immuCell.com>.

Contacts:

Michael F. Brigham, President and CEO

ImmuCell Corporation

(207) 878-2770

Joe Diaz, Robert Blum and Joe Dorame

Lytham Partners, LLC

(602) 889-9700

iccc@lythampartners.com

ImmuCell